BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 19448593)

  • 21. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
    Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S
    Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of the Bcl-2 negative germinal centre in patients with diffuse large B cell lymphoma treated with R-CHOP.
    Song MK; Chung JS; Shin DH; Seol YM; Shin HJ; Choi YJ; Cho GJ
    Leuk Lymphoma; 2009 Jan; 50(1):54-61. PubMed ID: 19152170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.
    Iqbal J; Meyer PN; Smith LM; Johnson NA; Vose JM; Greiner TC; Connors JM; Staudt LM; Rimsza L; Jaffe E; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; Chan WC
    Clin Cancer Res; 2011 Dec; 17(24):7785-95. PubMed ID: 21933893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial.
    Petrella T; Copie-Bergman C; Brière J; Delarue R; Jardin F; Ruminy P; Thieblemont C; Figeac M; Canioni D; Feugier P; Fabiani B; Leroy K; Parrens M; André M; Haioun C; Salles GA; Gaulard P; Tilly H; Jais JP; Molina TJ
    Ann Oncol; 2017 May; 28(5):1042-1049. PubMed ID: 28327893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL.
    Ott G; Ziepert M; Klapper W; Horn H; Szczepanowski M; Bernd HW; Thorns C; Feller AC; Lenze D; Hummel M; Stein H; Müller-Hermelink HK; Frank M; Hansmann ML; Barth TF; Möller P; Cogliatti S; Pfreundschuh M; Schmitz N; Trümper L; Loeffler M; Rosenwald A
    Blood; 2010 Dec; 116(23):4916-25. PubMed ID: 20736456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
    Gutiérrez-García G; Cardesa-Salzmann T; Climent F; González-Barca E; Mercadal S; Mate JL; Sancho JM; Arenillas L; Serrano S; Escoda L; Martínez S; Valera A; Martínez A; Jares P; Pinyol M; García-Herrera A; Martínez-Trillos A; Giné E; Villamor N; Campo E; Colomo L; López-Guillermo A;
    Blood; 2011 May; 117(18):4836-43. PubMed ID: 21441466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.
    Yan LX; Liu YH; Luo DL; Zhang F; Cheng Y; Luo XL; Xu J; Cheng J; Zhuang HG
    PLoS One; 2014; 9(8):e104068. PubMed ID: 25090026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy.
    Hong J; Park S; Park J; Kim HS; Kim KH; Ahn JY; Rim MY; Jung M; Sym SJ; Cho EK; Shin DB; Lee JH
    Leuk Lymphoma; 2011 Oct; 52(10):1904-12. PubMed ID: 21718130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab.
    Jais JP; Haioun C; Molina TJ; Rickman DS; de Reynies A; Berger F; Gisselbrecht C; Brière J; Reyes F; Gaulard P; Feugier P; Labouyrie E; Tilly H; Bastard C; Coiffier B; Salles G; Leroy K;
    Leukemia; 2008 Oct; 22(10):1917-24. PubMed ID: 18615101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.
    Tzankov A; Leu N; Muenst S; Juskevicius D; Klingbiel D; Mamot C; Dirnhofer S
    J Hematol Oncol; 2015 Jun; 8():70. PubMed ID: 26071053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunophenotype classification and therapeutic outcomes of Chinese primary gastrointestinal diffuse large B-cell lymphoma.
    Zhang Z; Shen Y; Shen D; Ni X
    BMC Gastroenterol; 2012 Jun; 12():77. PubMed ID: 22726454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy.
    Nyman H; Adde M; Karjalainen-Lindsberg ML; Taskinen M; Berglund M; Amini RM; Blomqvist C; Enblad G; Leppä S
    Blood; 2007 Jun; 109(11):4930-5. PubMed ID: 17299093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
    Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
    J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunophenotyping of diffuse large B-cell lymphoma (DLBCL) defines multiple sub-groups of germinal centre-like tumours displaying different survival characteristics.
    Anderson JJ; Fordham S; Overman L; Dignum H; Wood K; Proctor SJ; Crosier S; Angus B; Culpin RE; Mainou-Fowler T
    Int J Oncol; 2009 Nov; 35(5):961-71. PubMed ID: 19787248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP.
    Shustik J; Han G; Farinha P; Johnson NA; Ben Neriah S; Connors JM; Sehn LH; Horsman DE; Gascoyne RD; Steidl C
    Haematologica; 2010 Jan; 95(1):96-101. PubMed ID: 19797725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
    Visco C; Li Y; Xu-Monette ZY; Miranda RN; Green TM; Li Y; Tzankov A; Wen W; Liu WM; Kahl BS; d'Amore ES; Montes-Moreno S; Dybkær K; Chiu A; Tam W; Orazi A; Zu Y; Bhagat G; Winter JN; Wang HY; O'Neill S; Dunphy CH; Hsi ED; Zhao XF; Go RS; Choi WW; Zhou F; Czader M; Tong J; Zhao X; van Krieken JH; Huang Q; Ai W; Etzell J; Ponzoni M; Ferreri AJ; Piris MA; Møller MB; Bueso-Ramos CE; Medeiros LJ; Wu L; Young KH
    Leukemia; 2012 Sep; 26(9):2103-13. PubMed ID: 22437443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.
    Wilson WH; Dunleavy K; Pittaluga S; Hegde U; Grant N; Steinberg SM; Raffeld M; Gutierrez M; Chabner BA; Staudt L; Jaffe ES; Janik JE
    J Clin Oncol; 2008 Jun; 26(16):2717-24. PubMed ID: 18378569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53.
    Cai Q; Tu M; Xu-Monette ZY; Sun R; Manyam GC; Xu X; Tzankov A; Hsi ED; Møller MB; Medeiros LJ; Ok CY; Young KH
    Mod Pathol; 2017 Jun; 30(6):854-876. PubMed ID: 28281555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
    Pedersen MØ; Gang AO; Brown P; Pedersen M; Knudsen H; Nielsen SL; Poulsen T; Wirenfeldt Klausen T; Høgdall E; Nørgaard P
    PLoS One; 2017; 12(10):e0186983. PubMed ID: 29088292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Expression of CD68, cyclin D1 and rearrangement of bcl-6 gene are adverse prognostic factors in diffuse large B-cell lymphoma].
    Liang X; Wang J; Bai W; Sun R
    Zhonghua Bing Li Xue Za Zhi; 2015 Aug; 44(8):559-64. PubMed ID: 26705179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.